INTRODUCTION
G protein-coupled receptors (GPCRs) play central roles in cell communication and physiology. These receptors form the largest class of proteins considered for drug discovery and are the targets for about 30% of pharmaceuticals in current use (Wacker et al., 2017) . A key advance in GPCR research was the recognition that these receptors are highly dynamic proteins that adopt multiple conformations upon activation by different ligands. As a corollary, distinct agonists acting at the same receptor can engage different effector subsets, modifying cellular outcomes differently and producing distinguishable effects at system level. This concept, termed biased signaling or functional selectivity (Galandrin et al., 2007; Kenakin, 2011) forms the basis of many high-throughput screening programs to develop novel drugs with improved therapeutic potential (Wacker et al., 2017) . At present, biased activities are typically established in engineered heterologous cells, overexpressing receptors and effectors, and the translation to native tissues and living organisms remains a true challenge (Zhou and Bohn, 2014) . Although critical for drug development strategies, the extent to which biased signaling in recombinant cells relates to physiology remains largely unknown.
The mu opioid receptor (MOR), a GPCR family member, has emerged as a highly debated drug target as the opioid crisis intensifies in Western countries (Compton et al., 2016) . This major public health crisis stems from the overprescription of opioid pain medication, leading to a sharp increase of deaths by overdoses and a devastating shift to heroin (Compton et al., 2016) and fentanyl (Suzuki and El-Haddad, 2017) abuse. However, the pain-relieving efficacy of opioids remains unmatched and, more than ever, developing opioids with low abuse potential and reduced side effects is a major goal in pain research. Among current strategies (Olson et al., 2017) toward safer opioid analgesics (Siuda et al., 2017) , the design of biased MOR agonists is considered most promising. Functional selectivity at MOR, with preferential engagement of inhibitory G proteins (Gai/o) (Gi-biased) or barrestins (barr-biased), is well established in heterologous cells (McPherson et al., 2010) . In addition, evidence from genetic mouse mutants has suggested that limiting barr2 recruitment at the receptor would maintain morphine analgesia but reduce adverse effects, including deadly respiratory depression (Zhou and Bohn, 2014) . These promising Gai/o-biased MOR agonists are thus developed using recombinant cell-based assays, leading notably to TRV130 (DeWire et al., 2013) undergoing clinical trials (Singla et al., 2017; Siuda et al., 2017) (and see clinicaltrials.gov), or PZM21, a novel chemotype optimized from in silico modeling and docking studies (Manglik et al., 2016) . Recently, the extent of Gai versus barr bias for MOR ligands was proposed to correlate at the behavioral level with donor) dissociates from the bg-GFP10 (a, acceptor) dimer, which results in a decrease in BRET 2 signal. Data are expressed as % of BRET signal for MOR (untagged), four replicate experiments. (C) G protein activation profile for MOR and MOR-Venus. On top, schematic representation of the pan Gg/GRK-based BRET 2 assay, donor) , and GRK2-GFP10 (a, acceptor). Upon ligand binding to the receptor, the Ga subunit dissociates from the bg-RlucII dimer allowing recruitment of GRK2-GFP10 increasing the BRET 2 signal. BRET 2 was measured 10 min after stimulation with 30 mM Met-Enk. Mock shows MOR-mediated activation of endogenous G proteins. Data are expressed as percentage mock response (n = 3-5 independent experiments, one-way ANOVA). (D) There was no difference in G protein signaling in the striatum of MOR and MOR-Venus the analgesia or respiratory depression therapeutic window (Schmid et al., 2017) . Until now, however, evidence for the direct translation of biased signaling observed in engineered cells to living neurons is lacking. In this study, we designed a novel strategy ( Figure 1A ) to address this key point, and our data provide the long-awaited demonstration that biased signaling properties of both traditional and newly developed MOR agonists operate similarly in native neurons.
RESULTS

Designing the MOR-Venus Tool in Recombinant Cells
We first designed a customized version of MOR amenable to distinguish agonist activities in a physiological context. As agonist-induced MOR trafficking is considered a hallmark of biased signaling (Williams et al., 2013) , and is a measurable endpoint in vivo, we created an MOR version that would be traceable in tissues. Guided by our previous work (Erbs et al., 2015) , we fused the mouse MOR to Venus-YFP (MOR-Venus) the most versatile fluorophore compatible with resonance energy transfer (RET) biosensors (Breton et al., 2010) and best detectable in living cells (Nagai et al., 2002) . We tested the integrity of MOR-Venus signaling in HEK293 cells, typically used for drug screening and signaling assays. In a Gai/Gg-dissociation bioluminescence RET 2 (BRET) biosensor assay (Gales et al., 2006) , the reference MOR endogenous opioid Metenkephalin (Met-Enk) stimulated Gai1 with similar potency and efficacy in recombinant MOR (untagged) and MOR-Venus (tagged) receptors ( Figure 1B) . In a pan G protein Gg/GPCR kinases (GRKs) recruitment-based BRET 2 assay (Karamitri et al., 2018) , absolute values for basal G protein signaling were comparable between untagged and tagged receptors ( Figure S1A ). Furthermore, Met-Enk promoted activation of all Gai and Gao family members, but was inactive at Gaq for both MOR and MOR-Venus ( Figure 1C ). Also, similar preference toward GaoA, GaoB, Gai2, and Gai3 was found for the two receptors. Finally, we created a human version of MOR-Venus, and tested both mouse and human receptors for the activation of 7 mouse and 14 human Ga subunits, using the Gg/GRK-based BRET 2 assay (Figures S1B-S1E). This comprehensive profiling showed no difference in Met-Enk responses, whether the receptor was mouse or human or tagged or untagged, or whether Ga was mouse or human. Altogether, these data suggest that the Venus fusion does not alter receptor signaling and supports data translatability between mouse and human MOR signaling.
Creating the MOR-Venus Mouse to Tackle Physiological Signaling
We then created the corresponding MOR-Venus knock-in mouse line by homologous recombination, so that MOR-Venus is expressed in place of the native receptor ( Figure S2A ). MOR mRNA levels in brain samples from Oprm1 Venus/Venus homozygous (MOR-Venus mice), Oprm1 Venus/+ heterozygous, and Oprm1 +/+ control littermates were comparable ( Figure S2B ), and [D-Ala 2 , N-MePhe 4 , Gly-ol]-enkephalin (DAMGO)induced G protein activation in striatal membranes showed superimposable dose-responses for all three genotypes ( Figure 1D ). Morphine-induced locomotor stimulation ( Figure 1E ) and analgesia ( Figure 1F ) were also intact in MOR-Venus mice, indicating altogether that the MOR-Venus receptor is expressed at levels comparable to endogenous receptors in the animal and is fully functional. MOR-Venus distribution analysis showed co-localized expression of both tagged and untagged receptors in heterozygous animals ( Figure S3 ). Mapping throughout the nervous system revealed an MOR-Venus expression pattern consistent with previous reports (Figures S4A-S4C, Table S1 , and see Erbs et al., 2015) and provided additional details on MOR localization in soma or fibers ( Figure 1G ). Finally, MOR-Venus expression in sensory neurons Figure 1 . Continued mice. [S 35 ] GTPyS incorporation in striatal membranes prepared from MOR +/+ (wild-type controls), MOR Venus/+ (heterozygous knock-in), and MOR Venus/Venus (homozygous knock-in) mouse littermates, in response to increasing DAMGO concentrations. Data are expressed as mean % activation G SEM of [S 35 ] GTPyS binding above basal (no agonist) level (3-4 independent experiments with duplicates). Two-way ANOVA found no difference of drug effects across genotypes. (E) MOR +/+ and MOR Venus/Venus injected with morphine (40 mg/kg i. p.) or saline show similar locomotor responses (10-min bins). Data are expressed as the distance traveled in centimeters (n = 5-6/group, two-way ANOVA, significant drug effect, no genotype effect). (F) Morphine analgesia is intact in MOR and MOR-Venus mice. Animals were injected with morphine (5 or 10 mg/kg intraperitoneally) or saline. Left, analgesia in the hot plate test, measured by latency to lick the hind paw (n = 3-4/group, two-way ANOVA, significant drug effect at 10 mg/kg, no genotype effect). Right, analgesia in the tail immersion test (52 C), measured by tail withdrawal latency (n = 3-4/group, two-way ANOVA, significant drug effect at 5 and 10 mg/kg, no genotype effect). Cutoff to be removed from the test (10 s) is indicated by a broken line. (G) Whole-brain mapping of MOR-Venus expression (quantification in Table S1 ). The scheme shows an overview of MOR-Venus distribution in soma (blue), fibers (green), or both (gold) across brain areas enriched for the receptor. MH, medial habenula; fr, fasiculus retroflexus; IPN, interpeduncular nucleus; CP, caudate putamen; PVT, paraventricular thalamus; PB, parabrachial nucleus. (H) Sections of MOR-Venus dorsal root ganglia (DRG) detect MOR either directly (intrinsic, Venus fluorescence) or using Venus amplification (anti-Venus antibody, amplified). All data in (B-F) are presented as mean G SEM. Statistical significance is defined as *p < 0.05, **p < 0.01, ***p < 0.001. On top, schematic representation of the Gai2/Gg2-BRET 2 biosensor assay with BRET 2 sensors (Gai2-RlucII, d, donor; Gg2-GFP10, a, acceptor). Cells were stimulated 10 min with increasing concentrations of the indicated compound. Data are expressed as % of Met-Enk response n = 3-7 independent experiments. (B) barr2 recruitment in HEK293 cells. On top, schematic representation of the MOR/barr2 BRET 1 biosensor assay. Upon activation, RlucIItagged barr2 (d, donor) is recruited to MOR-Venus (a, acceptor), resulting in increased BRET 1 signal. Cells were stimulated 10 min with increasing concentrations of the indicated compound. Data are expressed as mean % of the maximal response induced by Met-Enk (n = 4-9 independent experiments).
(C) Receptor internalization in HEK293 cells. On top, schematic representation of the MOR/CAAX BRET 2 biosensor assay, used to monitor receptor disappearance from the plasma membrane (PM). MOR-RlucII is the donor (d), and rGFP-tagged CAAX is the acceptor (a). HEK293 cells were exposed to increasing concentrations of MOR agonists for 30 min. Data are expressed as % of Met-Enk response (4-7 independent experiments). (D) Receptor translocation to endosomes in HEK293 cells. On top, schematic representation of MOR/FYVE BRET 2 biosensor assay, used to monitor receptor translocation to early endosomes (EE). MOR-RlucII is the donor (d), and rGFP-tagged FYVE is the acceptor (a). HEK293 cells were exposed to increasing concentrations of MOR agonists for 30 min. Data are expressed as mean % of the maximal response induced by Met-Enk (n = 4-7 independent experiments). (E-G) Receptor redistribution in DRG neurons. (E) DRG neurons from adult MOR-Venus mice were dissociated and exposed to 1 mM MOR agonist for 10 min. Representative of dorsal root ganglia (DRGs, see Figure 1H ) matched the known predominant MOR expression in first-order nociceptive neurons (Scherrer et al., 2009 ). MOR-Venus mice, therefore, provide an ideal physiological assay system to profile MOR agonist activities, under conditions that recapitulate native receptor expression.
Profiling Drug Activities for 10 Mu Opioid Agonists in Recombinant Cells
Next, we measured the activities of selected opioid agonists at MOR-Venus, in the HEK293 cell heterologous system. The 10 selected compounds included prescribed or abused MOR agonists (morphine, oxycodone, buprenorphine, fentanyl), prototypic peptidic compounds (Met-Enk, DAMGO, endomorphin-1), and Gai/o-biased agonists from recent drug discovery efforts (TRV130, PZM21) ( Figure 1A ).
In HEK293 cells, concentration-response curves for Gai2 activation using Gai/Gg-BRET 2 showed highly similar curves for all the drugs, except for oxycodone, which had a trend of lower potency and for buprenorphine, which had significantly lower efficacy and potency than Met-Enk ( Figure 2A and Table S2 ). Testing all three Gai subunits in the Gai/Gg-BRET 2 biosensor assay revealed no significant difference in basal activity for MOR-Venus and untagged MOR ( Figures S5A and S5B) , and highly similar drug responses for Gai1 and Gai3 ( Figures S5C and S5D ).
To test barr2 recruitment, we used the Venus fusion of MOR as the BRET 1 acceptor for barrestin-RlucII (Figure 2B) and obtained robust BRET responses, indicating that MOR-Venus itself may be used as a biosensor. We obtained a wide range of responses for the 10 drugs, suggesting that barr2 engagement is a better differentiating factor than the Gai response. Co-expressing GRKs 2, 5, or 6 increased barr2 recruitment for most drugs ( Figure S6B ) as expected (Ribas et al., 2007; Williams et al., 2013) , although notably the effect was modest for TRV130, PZM-21, and buprenorphine (Tables S3A and S3B ). Of note, the Venus tag did not modify basal barr2 recruitment, as there was no significant difference between MOR-Venus and untagged MOR in a control experiment measuring basal barr2 recruitment ( Figure S6A ).
We next used our recently developed enhanced bystander (ebBRET) biosensors ( Figures S7A and S7D ) to monitor receptor redistribution upon agonist exposure , an event tightly linked to barr2 engagement. In receptor-independent control experiments, we found that untagged MOR and MOR-Venus showed no statistical difference in their activities to translocate barr2 to endosomes, either in the absence of agonist ( Figure S7B ) or in the presence of Met-Enk ( Figure S7C ). As the MOR tag had no apparent effect in this assay, we next compared the 10 selected compounds using MOR-RlucII as the donor to directly monitor receptor redistribution upon agonist exposure ( Figure S7D ). As expected, Met-Enk promoted receptor disappeared from the plasma membrane (PM), detected using the rGFP-CAAX biosensor, and the receptor concomitantly accumulated in early endosomes (EE), detected using rGFP-FYVE ( Figures S7D and S7E ). As for barr2 profiling, testing the 10 drugs showed a wide range of activities in both CAAX ( Figure 2C ) and FYVE ( Figure 2D ) assays. The observation that buprenorphine, and to a lesser extent oxycodone and morphine, increased the CAAX BRET signal (Table S4 ) suggests that these drugs may, in fact, inhibit constitutive endocytosis or recruit more receptors to the PM. In the FYVE assay, agonists induced receptor translocation to endosomes to a similar extent for all compounds except morphine, oxycodone, PZM21, TRV130, and buprenorphine, which had significantly lower efficacies Radial graphs illustrating the specific activity signature (see Transparent Methods) for each drug (colored line) compared with Met-Enk (gray line). Upper radial plots: dose-response curves for the HEK293 cell data were used to derive the logarithm of the ''transduction coefficients'' (Dlog(t/Ka)) to integrate efficacy (t) and affinity (Ka). Lower radial plots integrate single concentration effect in neurons and dose-response effects in HEK293 cell data as follows: dose-response curves were used to fit HEK293 cell data into an Emax/EC 50 ratio to estimate signaling efficacy, whereas the neuronal (DRG) data ( Figure 2G or when compared with Met-Enk ( Figure 2D and Table S5 ). Overexpression of GRK2 alone or in the presence of barr2 ( Figures S7F and S7G ) enhanced both the loss of receptor from the PM (CAAX) and their translocation to EE (FYVE) for most drugs (Tables S4 and S5 ). Exceptions were PZM21, TRV130, and buprenorphine with significantly lower efficacies in the CAAX assay when compared with Met-Enk in the presence of GRK2 and barr2 ( Figure S7F and Table S4) , and, remarkably, buprenorphine maintained a significantly lower efficacy in the trafficking assay ( Figure S7G and Table S5 ), whereas TRV130 and PZM21 responded to a similar efficacy as Met-Enk.
Profiling Drug Activities for 10 Mu Opioid Agonists in Native Neurons
We then tested the activities of the 10 drugs on DRG neurons, which we extracted from adult MOR-Venus mice. These cells are most relevant to pain control and well suited for quantification by confocal imaging ( Figure S8A ). PM was labeled using WGA-AlexaFluor594, and fluorescence in intracellular (IC) compartment versus PM was compared ( Figure 2F thereafter called IC assay). DAMGO dose-and time-dependently increased the translocation of MOR-Venus signal intracellularly ( Figure S8B ), indicating the sub-maximal dose as 1 mM and 10-min time point for the best assay conditions to compare the 10 drugs for their ability to promote endocytosis in neurons. MOR-Venus DRG neurons were then exposed to each drug and imaged ( Figures 2E-2G , S9A, and S9B). A range of effects was obtained, from compounds producing MOR-Venus redistribution similar to Met-Enk-induced responses (DAMGO) to those that significantly differed either only weakly redistributing (TRV130, oxycodone), or even increasing MOR-Venus at the PM (PZM21 and buprenorphine) (Figures 2G and S9A and Table S6 ). Furthermore, agonist-induced receptor redistribution was not modified by the level of MOR-Venus expression, as high-and low-MOR-Venusexpressing neurons showed similar responses ( Figure S10A ) and Pearson correlation between IC assay and total MOR-Venus signals was not significantly correlated (r = 0.3069, p = 0.3883) for the selected 10 compounds ( Figure S10B ).
We designed another assay to measure MOR-Venus co-localization to EEs (Figures 2H-2J and S11A-S11C) by overlaying EEA1-positive vesicles in DRG neurons with MOR-Venus fluorescence, and counting for double-positive signals. Overall, drug treatment did not significantly modify the average number of EEA1-labeled vesicles per cell when compared with Met-Enk ( Figure S11C ) but increased the percentage of vesicles showing EEA1 and MOR-Venus co-localization ( Figure 2J ). Again, drug effects were compared to Met-Enk responses (Table S7 ) and ranged from similar (DAMGO) receptor to endosome translocation to none (PZM21), or even opposing (buprenorphine) effect ( Figure 2J ), consistent with the data obtained with the IC assay.
Establishing Drug Signatures
Altogether the 10 drugs showed a wide range of activities. We next further estimated drug signaling efficacy using the operational model integrating logarithms of the transduction coefficient (Dlog(t/Ka)) derived from concentration-response curves obtained in HEK293 cells (see Methods and Figure 3 , upper radial plots). These transduction coefficients were further used to estimate the bias between either Gai2 and barr2 or MOR localization to EE compartments (FYVE assay) (Table S8) . Notably, this analysis found morphine, oxycodone, TRV130, PZM21, and buprenorphine to be Gai2-biased for both estimates of bias. Fentanyl showed bias toward Gai2 over barr2 in the absence of additional GRK2; however, when GRK2 was added, barr2 recruitment (Table S3B ) was increased to a similar efficacy level as Met-Enk response suggesting that this Gai2 bias may be dependent on GRK2 availability.
To better illustrate the data, we integrated the overall efficiency of the drugs using the Emax/EC 50 ratios in HEK293 cells with the 1 mM drug responses in native neurons for each drug in radial graphs (see Methods and Figure 3 , lower radial plots), providing a set of MOR agonist signatures. Note that only the HEK293 cell data were derived from concentration-effect values. Agonist profiles formed a continuum, but can essentially be discussed as three groups. DAMGO, endomorphin-1, loperamide, and fentanyl were close to the reference Met-Enk, showing both efficient Gai and barr2 activities in HEK293 cells, consistent with previous , where all drug treatments were done at submaximal dose ( Figure S8B ), were normalized as ((compound/Met-Enkephalin)-Met-Enkephalin), thus Met-Enkephalin response is set to 0. For both HEK293 cells and native neurons positive and negative values denote a better or a lower response when compared with Met-Enkephalin. Top left, the scale is highlighted in yellow on the reference Met-Enk radial plot (min À5 to max 2 with intervals of 1). The legend indicates the assay abbreviations. # Indicates a drug effect that was too low or could not be fitted to the operational model.
iScience 14, 47-57, April 26, 2019 studies (Pradhan et al., 2012) . Moreover, the four drugs also showed comparable trafficking effects in HEK293 cells (enhanced by GRK2/barr2 overexpression) and DRG neurons. The second and third groups had in common lower effects in the CAAX assay that made them unable to be fitted to the operational model. In the second group, morphine and oxycodone shared a similar Gai-biased profile, although oxycodone was less active overall. Morphine in HEK293 cells showed efficient Gai signaling, whereas barr2 engagement was marginally observed unless GRKs were overexpressed. Morphine was also able to induce receptor redistribution in HEK293 cells (FYVE and CAAX with GRK2/barr2 overexpression) as well as under physiological conditions (both IC and EE assays). The third group includes TRV130, PZM21, and buprenorphine; all were Gai2 biased, but only buprenorphine showed insensitivity to GRK2/barr2 overexpression in the CAAX and FYVE assays in HEK293 cells. In neurons, subtle differences further distinguished the three compounds. TRV130 moderately increased endosomal co-localization ( Figure 2J ), whereas PZM21 and buprenorphine did not, possibly due to MOR-Venus externalization (Zaki et al., 2000) and/or stabilization at the PM. Finally, although Gai-biased profiles were anticipated for TRV130 (Siuda et al., 2017) and PZM21 (Manglik et al., 2016) , the extreme position of buprenorphine in our neuron-based assays was striking. Similar to the trafficking responses in the neurons, buprenorphine showed the lowest efficacy in HEK293 trafficking assays despite addition of GRK2/barr2 (Tables S4 and S5 ) displaying a signaling signature presumably optimal for a better therapeutic safety window (Schmid et al., 2017) . This long-standing prescribed drug for opioid addiction treatment (Ayanga et al., 2016) , in fact, has been neglected for pain treatment and may be reconsidered Khanna and Pillarisetti, 2015) .
Correlating Trafficking Activities in Recombinant Cells and DRG Neurons
Finally, we compared activities of the compounds in the two experimental systems, to directly assess the translatability of HEK293 cell responses to neurons. As IC redistribution and EEA1 colocalization in DRG neurons are best comparable with CAAX and FYVE biosensor responses in HEK293 cells, respectively, we used E max from HEK293 cell dose-response curves (Figures 2C and 2D and Tables S4 and S5 ) and the submaximal-dose-derived percentage Met-Enk neuronal responses ( Figures 2G and 2J ) for correlation analysis. We found strong positive correlation for both dataset comparisons ( Figure 4A , r = 0.8784 and ***p = 0.0008; Figure 4B , r = 0.9141 and ***p = 0.0002). This result demonstrates that biased signaling of MOR agonists, typically established in traditional drug screening systems, is physiologically relevant to neurons.
DISCUSSION
GPCRs constitute the largest family of protein targets for approved drugs in the United States and European Union (Sriram and Insel, 2018) , and emerging strategies to design new GPCR-based therapeutics A B take advantage of biased signaling to improve efficacy and safety Hauser et al., 2017) . At present, drug signaling profiles are established using overexpressed receptors and effectors in nonneuronal cells, which are practical for biosensor-based assays, but the translation to endogenous receptors in living neurons remains a major question as receptor density is lower by several orders of magnitude and effector availability is essentially unknown (Luttrell et al., 2018) . Here we used the MOR as a model receptor to approach this question. The alarming context of the current opioid epidemic has led to developing novel Gai/o-biased MOR agonists (TRV130 and PZM21) to limit adverse opioid effects (DeWire et al., 2013; Manglik et al., 2016; Schmid et al., 2017) , which we studied here together with clinically used and abused opiates.
Earlier studies that have examined a large set of MOR agonists' ability to activate G proteins, phosphorylate MOR, recruit barr2, and internalize the receptor (McPherson et al., 2010) have primarily been performed in transfected HEK293 cells. Here we developed a knock-in mouse line, which produces a detectable version of the receptor (MOR-Venus) in place of the native receptor. In HEK293 cells, basal G protein activation profile, barr2 recruitment, and trafficking to endosomes were comparable for untagged and MOR-Venus-tagged receptors. In the mouse, MOR-Venus mediated behavioral morphine effects (hyperlocomotion and analgesia) similar to the native receptor. MOR-Venus is therefore fully functional in both overexpression HEK293 cell-based assays and in the mouse, providing an ideal tool to compare druginduced trafficking under artificial and physiological conditions. We found that, the Gai/o-biased TRV130, PZM21, and buprenorphine induced virtually no receptor redistribution or endosome translocation, whereas clinical and peptidic ligands showed limited to strong trafficking effects, and, importantly, these activities were remarkably correlated in recombinant and physiological assays. Our study therefore provides a long-awaited validation of early-stage preclinical efforts for MOR drug discovery and also holds promise for GPCR drug discovery in general.
Trafficking analyses provided the best differentiation of drug effects in HEK293 cells, and receptor redistribution at subcellular level may represent a further research path to characterize drug activities. Future analysis of MOR-Venus trafficking in distinct cellular compartments may further differentiate drug activities in native neurons and provide novel and perhaps translatable insights into agonist-dependent MOR signaling in vivo (Irannejad et al., 2017) . Recently, location-specific MOR activation was monitored using a genetically encoded conformational biosensor, and revealed ligand-dependent signaling at the subcellular level, with opioid alkaloid effects detected at the level of Golgi in both soma and dendrites, whereas opioid peptide signaling remaining confined to the PM and EE (Stoeber et al., 2018) . Moving forward, these studies and ours reveal novel facets of drug activities by directly observing receptor redistribution intracellularly, which will further refine drug activity profiles. MOR-Venus mice, which were developed for optimal RET, will be a unique tool to develop next-generation biosensors and characterize biased opioid signaling and trafficking in vivo.
Buprenorphine (Subutex), which was long used as a treatment for opioid addiction, appears to be a remarkable drug in both overexpression and native systems of this study. In transfected cells, the overexpression of GRK2 and barr2, known to enhance agonist-induced trafficking, increased responses for all the compounds, including TRV130 and PZM21, but buprenorphine remained largely insensitive. In native neurons, buprenorphine showed the most significant PM-receptor retaining activity in both redistribution and endosome localization assays. The buprenorphine signature, therefore, is closer to recently developed Gibiased drugs (TRV 130 and PZM21) than any other drug tested in this study. This observation suggests that this clinically safe and efficient analgesic is worth revisiting for pain management as an alternative to common clinical opioids (fentanyl and morphine) .
To conclude, moving from neuronal cells to whole-organism responses will address yet another level of complexity, and how findings from this study translate to whole animals remains to be seen. Recent improvements in whole animal imaging, for second messengers (Ca 2+ miniscopes, cAMP in vivo biosensors) will be instrumental to fully profile drug signaling in vivo (Girven and Sparta, 2017; Kerr and Nimmerjahn, 2012) , and ultimately relate circuit-level understanding of biased signaling (Urs et al., 2016) to the amazingly distinct properties of traditional and innovative MOR agonists at the behavioral level (Schmid et al., 2017) .
Limitations of the Study
The resolution of MOR-positive DRG neurons was limited in the present study to neurons detected in our primary culture conditions. Future studies, on intact DRG slices or intravital whole animal imaging should improve the characterization of MOR ligands across all DRG neuronal subtypes and elucidate key actions of these MOR neuronal subsets in pain.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file. 
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Supplemental Information Figure 1G and Table S1 ) show brain areas with highest MOR expression. Scale bars for macroview insets are 2 mm, magnified views are 20 µm. Annotations: lateral habenula (LH), caudate putamen (CP), paraventricular thalamus (PVT) and parabrachial nucleus (PB). Figure 2A . Pharmacological properties for Gαi1, Gαi2 and Gαi3 biosensors are described in Table S2 . Data are expressed as % of Met-Enkephalin (Met-Enk) response (n= 3-7 independent experiments). All data are shown as mean ± SEM. Annotations: PM, plasma membrane. cells were co-transfected with MOR-Venus and βarrestin2-RlucII only (Mock) or with either GRK2, GRK5 or GRK6 and were stimulated with increasing concentrations of the indicated compounds for 10 min. Mock curves are also shown in Figure 2B . The pharmacological properties of the 10 compounds in the absence or presence of GRK2, GRK5 or GRK6 are summarized in Table S3 . Data are expressed as % of Met-Enkephalin (Met-Enk) response in the absence of GRK, (n= 4-9 independent experiments). Annotations: PM, plasma membrane. Table S1 Regional MOR-Venus expression. Related to Figure 1 . Amplified MOR-Venus expression was mapped in 3-4 animals and categorized according to the Allen Brain Atlas. Areas are ranked according to degree of expression: very low (+), low (++), moderate (+++) or high (++++).
Table S2
Ligand-induced MOR-mediated activation of mouse Gαi proteins. Related to Figure 2 . Data table summarizing the pharmacological properties of the selected compounds for Gαi1, Gαi2 and Gαi3 activation (see Figure 2A and S5C-D). HEK-293 cells were cotransfected with MOR-Venus receptor construct, Gβ1, Gγ2-GFP10 (acceptor BRET 2 sensor) and RlucII-tagged Gαi1, 2 or 3 (donor BRET 2 sensor). Cells were stimulated for 10 minutes with increasing concentrations of the indicated compound. Emax values are expressed as mean ± SEM % of the maximal response induced by Met-Enkephalin (Met-Enk) . Potency values are expressed as LogEC50 ± SEM (EC50 M). Data are expressed as a mean of 3-7 independent experiments. *P<0.05, ** P<0.005, *** P<0.0001 vs Met-Enk condition (one-way ANOVA, followed by Dunnett post-hoc test).
Gαi1
Gαi2 Gαi3 Emax (%) LogEC50 Emax (%) LogEC50 Emax (%) LogEC50 Met-Enkephalin 100,0 ± 3,8 -7,61 ± 0,08 100,0 ± 5,7 -7,28 ± 0,13 100,0 ± 12,4 -6,50 ± 0,25 DAMGO 102,5 ± 3,5 -7,53 ± 0,07 97,2 ± 7,3 -7,75 ± 0,16 92,6 ± 10,7 -7,27 ± 0,25 Loperamide 125,9 ± 2,9*** -8,07 ± 0,05 109, 3 ± 6, 98 ± 0, 14 102, 6 ± 13, 69 ± 0, 4 ± 4, [0] [1] [2] [3] [4] [5] [6] [7] 49 ± 0, 08 99, 2 ± 5, 71 ± 0, 13 114, 4 ± 12, [5] [6] 81 ± 0, 23 Fentanyl 110, 6 ± 3, [4] [5] [6] [7] 73 ± 0, 07 101, 5 ± 5, [0] [1] [2] [3] [4] [5] [6] [7] 90 ± 0, 11 81, 6 ± 10, [2] [3] [4] [5] [6] [7] 98 ± 0, 26 Morphine 111, 8 ± 2, 97 ± 0, 05 103, 0 ± 7, [6] [7] 61 ± 0, 16 83, 6 ± 12, [3] [4] [5] [6] [7] 38 ± 0, 32 Oxycodone 110, 9 ± 3, [4] [5] [6] 58 ± 0, 07*** 104, 9 ± 6, 58 ± 0, 14 68, 8 ± 17, [0] [1] [2] [3] [4] 99 ± 0, 39 TRV130 85,2 ± 4,2** -7,86 ± 0,10 85,4 ± 4,5 -7,62 ± 0,12 62,2 ± 17,9* -6,05 ± 0,54** PZM21
105,4 ± 7,5 -7,83 ± 0,15 105,6 ± 6,3 -7,95 ± 0,13 84,1 ± 6,7 -7,15 ± 0,19 Buprenorphine 78,5 ± 4,5*** -8,67 ± 0,10*** 55,2 ± 9,9*** -8,40 ± 0,36** 65,7 ± 12,0 -6,70 ± 0,38 Table S3 Ligand-induced MOR-mediated activation of βarrestin2 recruitment. Related to Figure 2 . Data table summarizing the pharmacological properties of the selected compounds for βarr2 recruitment (see Figure 2B and S6B). For βarr2 recruitment, cells were co-transfected with MOR-Venus receptor (acceptor BRET 1 sensor) and βarrestin2-RlucII construct (donor BRET 1 sensor). Cells were stimulated 10 minutes with increasing concentrations of the indicated compound. 
Emax (%) LogEC50 Met-Enkephalin 100,0 ± 3,2 -6,07 ± 0,06 100,0 ± 2,7 -6,78 ± 0,06 100,0 ± 4,1 -6,61 ± 0,09 100,0 ± 2,7 -6,44 ± 0,05 DAMGO 98,2 ± 1,7 -6,29 ± 0,03 104,6 ± 2,3 -7,12 ± 0,05 106,7 ± 1,7 -6,99 ± 0,04 102,6 ± 2,2 -6,64 ± 0,05 Loperamide 77,1 ± 1,3*** -6,63 ± 0,03* 99,5 ± 2,2 -7,20 ± 0,05 96,1 ± 2,2 -7,11 ± 0,05 88,5 ± 2,3* -6,94 ± 0,05 Endomorphin-1 67,4 ± 1,5*** -6,63 ± 0,05* 96,6 ± 2,4 -7,27 ± 0,05 96,6 ± 1,7 -7,11 ± ,04* 85,1 ± 2,3** -6,92 ± 0,06 Fentanyl 49,4 ± 1,4*** -6,55 ± 0,06 86,7 ± 2,2 -7,24 ± 0,05 85,8 ± 1,8*** -7,13 ± 0,05* 71,9 ± 2,3*** -6,81 ± 0,07 Morphine 31,1 ± 0,9*** -6,48 ± 0,06 79,2 ± 1,7 -6,98 ± 0,04 76,6 ± 1,4*** -6,87 ± 0,04 54,9 ± 2,0*** -6,69 ± 0,08 Oxycodone 26,8 ± 1,0*** -5,49 ± 0,07* 75,6 ± 2,5** -5,85 ± 0,07* 78,6 ± 3,4*** -5,72 ± 0,08** 51,9 ± 2,7*** -5,63 ± 0,10** TRV130 4,1 ± 3,7*** -7,92 ± 1,74*** 9,3 ± 3,5*** -6,70 ± 0,84 7,4 ± 2,2*** -7,13 ± 0,66 1,9 ± 7,7*** -7,73 ± 8,28 PZM21 11,6 ± 3,5*** -7,27 ± 0,62*** 28,2 ± 5,2*** -5,86 ± 0,33 26,9 ± 3,0*** -6,60 ± 0,24 19,1 ± 4,7*** -6,27 ± 0,48 Buprenorphine 8,4 ± 0,5*** -7,03 ± 0,12*** 19,8 ± 1,9*** -7,73 ± 0,20* 17,2 ± 1,5*** -7,49 ± 0,19*** 10,5 ± 1,1*** -7,54 ± 0,21***
Emax (%) LogEC50 Met-Enkephalin 100,0 ± 3,2 -6,07 ± 0,04 98,1 ± 1,9 -6,78 ± 0,04 94,7 ± 2,9 -6,61 ± 0,06 98,2 ± 1,9 -6,44 ± 0,04 DAMGO 98,2 ± 1,7 -6,29 ± 0,03 131,6 ± 3,7*** -7,00 ± 0,06*** 103,8 ± 2,3 -6,92 ± 0,04*** 100,0 ± 2,4 -6,65 ± 0,05* Loperamide 77,1 ± 1,3 -6,63 ± 0,03 125,8 ± 4,1*** -7,18 ± 0,07*** 99,0 ± 3,2 -7,05 ± 0,07** 86,2 ± 2,5 -6,95 ± 0,06* Endomorphin-1 67,4 ± 1,5 -6,63 ± 0,05 120,1 ± 3,5*** -7,18 ± 0,06*** 96,6 ± 2,3** -7,00 ± 0,05** 83,0 ± 2,5 -6,92 ± 0,06 Fentanyl 49,4 ± 1,4 -6,55 ± 0,06 106,1 ± 3,0*** -7,16 ± 0,06*** 84,1 ± 1,9*** -7,03 ± 0,05** 69,9 ± 2,3** -6,81 ± 0,07 Morphine 31,1 ± 0,9 -6,48 ± 0,06 96,3 ± 2,9*** -6,94 ± 0,06** 75,3 ± 1,4*** -6,78 ± 0,04 57,1 ± 1,4** -6,73 ± 0,05 Oxycodone 26,8 ± 1,0 -5,49 ± 0,07 93,5 ± 3,3** -5,72 ± 0,07 77,8 ± 2,5* -5,63 ± 0,06 58,0 ± 2,1 -5,66 ± 0,07 TRV130 4,1 ± 3,7 -7,92 ± 1,74 12,0 ± 5,8 -6,76 ± 1,08 8,7 ± 3,2 -7,16 ± 0,77* 1,3 ± 7,5 -7,77 ± 11,56* PZM21 11,6 ± 3,5 -7,27 ± 0,62 29,9 ± 4,0 -6,15 ± 0,25* 33,4 ± 4,6 -6,58 ± 0,28 18,7 ± 5,5 -6,27 ± 0,57 Buprenorphine 8,4 ± 0,5 -7,03 ± 0,12 22,9 ± 2,4*** -7,68 ± 0,22 15,3 ± 1,3** -7,48 ± 0,18 10,7 ± 1,1 -7,36 ± 0,21 A B Table S4 Ligand-induced MOR internalization (CAAX assay). Related to Figure 2 . Data table summarizing the pharmacological properties of the selected compounds for receptor disappearance from plasma membrane (see Figure 2C and S7F). HEK-293 cells were cotransfected with MOR-RlucII (donor BRET 2 sensor) and CAAX-rGFP for plasma membrane localization (acceptor BRET 2 sensors). HEK-293 cells were stimulated 30 minutes with increasing concentrations of the indicated compound. Emax values are expressed as mean ± SEM % of the maximal response induced by Met-Enkephalin (Met-Enk). Potency values are expressed as LogEC50 ± SEM (EC50 M). Data are expressed as a mean of 3-7 independent experiments. * P<0.05, ** P<0.005, *** P<0.0001 vs Met-Enk condition (one-way ANOVA, followed by Dunnett post-hoc test).
Emax (%) LogEC50 Met-Enkephalin 100,0 ± 12,4 -5,75 ± 0,23 100,0 ± 4,3 -6,33 ± 0,08 100,0 ± 4,8 -6,08 ± 0,09 100,0 ± 5,4 -7,01 ± 0,12 DAMGO 102,7 ± 23,0 -5,43 ± 0,37 86,8 ± 5,3 -6,52 ± 0,12 80,7 ± 4,4 -6,16 ± 0,11 94,7 ± 7,7 -7,23 ± 0,18 Loperamide 59,7 ± 11,8 -6,49 ± 0,44 76,9 ± 5,5 -6,88 ± 0,15 66,1 ± 5,7 -6,71 ± 0,19 106,0 ± 5,2 -7,51 ± 0,11 Endomorphin-1 71,7 ± 13,7 -5,51 ± 0,33 99,5 ± 3,6 -6,98 ± 0,08 80,0 ± 4,2 -6,49 ± 0,11 120,6 ± 5,3 -7,62 ± 0,10 Fentanyl 37,2 ± 7,8 -6,42 ± 0,49 72,3 ± 2,6 -7,34 ± 0,08 61,1 ± 3,6 -7,05 ± 0,13 104,1 ± 2,3 -7,87 ± 0,05 Morphine -26,9 ± 11,3*** -7,65 ± 0,94*** 25,9 ± 5,0*** -6,02 ± 0,35 -5,1 ± 3,2*** -7,24 ± 1,36 78,0 ± 3,5 -6,53 ± 0,10 Oxycodone -41,8 ± 12,0*** -6,92 ± 0,67 43,9 ± 61,1*** -4,08 ± 1,16 -18,6 ± 6,6*** -8,64 ± 0,65*** 85,1 ± 15,3 -4,64 ± 0,22*** TRV130 -90,1 ± 36,9** -5,04 ± 0,55 -2,4 ± 8,3*** -7,53 ± 7,19 30,3 ± 34,3*** -4,59 ± 0,97 29,7 ± 4,2** -7,35 ± 0,32 PZM21 -35,3 ± 8,9** -6,75 ± 0,58 5,1± 12,5*** -6,14 ± 4,56 -1,2 ± 6,0*** -7,47 ± 11,43* 32,9 ± 4,7** -7,29 ± 0,32 Buprenorphine -72,7 ± 13,0*** -7,37 ± 0,42** -23,5 ± 5,9*** -7,05 ± 0,52 -27,9 ± 3,5*** -7,37 ± 0,28 2,7 ± 2,8** -7,95 ± 2,27*
Emax (%) LogEC50 Met-Enkephalin 100,0 ± 3,8 -6,00 ± 0,07 100,0 ± 2,4 -6,62 ± 0,05 100,0 ± 4,0 -6,39 ± 0,08 100,0 ± 2,3 -7,14 ± 0,05 DAMGO 106,9 ± 5,7 -6,52 ± 0,11 122,2 ± 5,5 -7,13 ± 0,09 106,3 ± 3,9 -6,74 ± 0,08 119,5 ± 3,3* -7,60 ± 0,06 Loperamide 105,1 ± 4,9 -7,00 ± 0,10 116,8 ± 5,0 -7,63 ± 0,09* 106,2 ± 5,8 -7,33 ± 0,12** 125,1 ± 5,0** -8,15 ± 0,08 Endomorphin-1 77,7 ± 5,2 -6,71 ± 0,14 109,5 ± 4,5 -7,33 ± 0,09 98,5 ± 4,8 -6,96 ± 0,11 114,9 ± 3,3 -7,92 ± 0,06 Fentanyl 72,5 ± 4,9 -6,83 ± 0,14 118,8 ± 4,7 -7,37 ± 0,08 95,5 ± 5,2 -7,03 ± 0,12 122,8 ± 5,5* -8,04 ± 0,09 Morphine 31,8 ± 5,6*** -9,00 ± 0,29** 66,6 ± 2,4*** -7,01 ± 0,07 34,3 ± 2,6*** -6,92 ± 0,17 89,0 ± 2,3 -6,99 ± 0,05 Oxycodone 18,6 ± 3,3*** -6,72 ± 0,36 46,2 ± 3,8*** -5,94 ± 0,16 25,3 ± 2,7*** -5,83 ± 0,22 75,6 ± 2,5** -5,98 ± 0,07* TRV130 11,2 ± 3,0*** -7,48 ± 0,57 41,4 ± 4,7*** -7,03 ± 0,24 25,2 ± 2,4*** -6,45 ± 0,20 90,3 ± 4,4 -7,47 ± 0,10 PZM21 15,3 ± 2,7*** -6,96 ± 0,37 41,3 ± 3,9*** -6,83 ± 0,20 27,1 ± 4,6*** -7,58 ± 0,37* 88,1 ± 5,0 -7,47 ± 0,12 Buprenorphine 11,3 ± 2,9*** -7,78 ± 0,53** 14,4 ± 2,8*** -7,02 ± 0,41*** 13,3 ± 3,0*** -8,62 ± 0,43*** 22,4 ± 3,2*** -7,16 ± 0,30 Table S5 Ligand-induced MOR translocation to early endosomes (FYVE assay). Related to Figure 2 . Data table summarizing the pharmacological properties of the selected compounds for receptor localization at the early endosome (EE) compartments (see Figure 2D and S7G). HEK-293 cells were co-transfected with MOR-RlucII (donor BRET 2 sensor) and rGFP-FYVE, for EE localization (acceptor BRET 2 sensors). HEK-293 cells were stimulated 30 minutes with increasing concentrations of the indicated compound. Emax values are expressed as mean ± SEM % of the maximal response induced by Met-Enkephalin (Met-Enk) . Potency values are expressed as LogEC50 ± SEM (EC50 M). Data are expressed as a mean of 3-7 independent experiments. * P<0.05, ** P<0.005, *** P<0.0001 vs Met-Enk condition (one-way ANOVA, followed by Dunnett post-hoc test). Figure 2G ). Figure 2J ). 
Plasmids
Plasmids encoding all the different non-tagged human G proteins used in this study were purchased from the Missouri University of Science and Technology (www.cdna.org). Nontagged mouse G proteins were either PCR-amplified using a Riken mouse cDNA book (Kawai & Hayashizaki, 2003) or synthesized (GeneART, ThermoFisher). All the G proteins were subcloned into pcDNA3.1(+) vector. Human (h) and mouse (m) MOR coding sequences were PCR-amplified and subcloned into pLVXi2P vector (Clontech, Mountain View, CA, USA) and pIRES vector (Invitrogen, Carlsbad, CA), respectively, using Gibson assembly (NEB, Ipswich, MA, USA). Protein sequence was optimized by the addition of a signal peptide (SP) (MKTIIALSYIFCLVFA) at the N-terminal domain sequence of the receptors. The Venus tag sequence was added to the C-terminus of mSP-MOR construct, through a short 5 amino acid linker (GSIAT). To generate mMOR-RlucII, mMOR coding sequence was PCR-amplified and inserted into pcDNA3.1/hygro(+)GFP10-RlucII vector (Leduc et al, 2009 ) after BamH1/Nhe1 digestion. The hSP-MOR coding sequence was PCR-amplified from pLVXi2P-SP-hMOR and subcloned into pIRES-Venus plasmid using Gibson assembly, removing the stop codon. GFP10 tag sequence was linked to the N-terminus of hGRK2 through a 7-amino acid linker (GSAGTGG) and GRK2-GFP10 was subcloned into pcDNA3.1 vector. hGγ3 coding sequence was fused in frame to the humanized Renilla luciferase II (RlucII) at its C-terminus and subcloned into pcDNA3.1 vector. RlucII-tagged mMOR, mGαi and mβ-arrestin2 were constructed by PCR-amplifying RlucII coding sequence and inserting it into pcDNA3.1(+) plasmid expressing the respective protein using Gibson assembly. mGγ2-GFP10 was generated by subcloning the GFP10-tag sequence into pcDNA3.1-mGγ2. rGFP-CAAX and rGFP-FYVE BRET biosensor constructs were generated as previously described .
HEK-293 cell culture, transfection and BRET measurement HEK-293 
G protein Activation in HEK-293 cells
For the G protein activation assay, cells were transfected with plasmids encoding either human (h)MOR, hMOR-Venus, mouse (m)MOR or mMOR-Venus. In Figure 1C and Figures S1A-S1E, cells were co-transfected with human/mouse Gβ1, human/mouse Gγ3-RlucII and human GRK2-GFP10 along with the indicated Gα subunits to measure the activation of the G proteins indirectly via the release of G-Rluc that can then interact with GRK2-GFP10, resulting in a BRET increase. Mock is a condition where cells were not transfected with any of the tested Gα proteins and reflects the background endogenous response. For Figure 1B and Figure S5 , the activation was assessed by directly measuring the separation between G and G in cells cotransfected with plasmids encoding mMOR-Venus or mMOR and mGβ1, mGγ2-GFP10 and the RlucII-tagged G subunits as indicated. Cells were stimulated 10 minutes with the indicated concentrations of agonists except for basal activity measured in the absence of agonist ( Figure  S5B) . In all cases G protein activation was measured using BRET 2 filter set.
βarrestin2 recruitment and receptor trafficking in HEK-293 cells Cells were transfected with mMOR-Venus and βarrestin2-RlucII constructs with ( Figure S6B ) or without ( Figure 2B and Figure S6B) hGRK2, hGRK5 or hGRK6. Cells were stimulated 10 minutes with the indicated concentrations of agonists and βarrestin2 recruitment was measured using BRET 1 filters set. Receptor redistribution and localization at the early endosome compartments was assessed by ebBRET in cells expressing mMOR-RlucII and either rGFP-CAAX (plasma membrane localization) or rGFP-FYVE (early endosome compartment) in the presence (Figure S7F-S7G ) or absence ( Figure 2C-2D ) of hGRK2 and hβarrestin2. Cells were stimulated with the selected compounds as indicated and translocation was assessed using BRET 2 filter set. For basal activity comparison between mMOR and mMOR-Venus, cells were transfected with either βarrestin2-RlucII and rGFP-CAAX constructs to assess βarrestin2 recruitment ( Figure S6A ) or βarrestin2-RlucII and rGFP-FYVE constructs as a surrogate for receptor trafficking (Figure S7B) , along with either mMOR or mMOR-Venus constructs. Both measurements were done using BRET 2 filter set.
Analysis of concentration-response curves
All the curves generated for the different pathways were fitted and analyzed using the nonlinear curve fitting equations in GraphPad Prism (v7.0, GraphPad Software, Inc, San Diego, CA, USA) to estimate the pEC50 values.
To illustrate data from both HEK-293 cells and native neurons in radial graphs (Figure 3) , drug overall efficiency obtained from concentration-response curves (in HEK-293 cells) was estimated by calculating Log(Emax/EC50) ratios for each compound and normalized to Met-Enkephalin using the formula Log (Emax/EC50)compound -Log(Emax/EC50)Met-Enkephalin. The antilogs were then calculated for drug responses in HEK-293 cells and responses were normalized to fit a scale of -1 to +1 using the formula (compound -Met-Enkephalin)/(compound + Met-Enkephalin). To illustrate responses in native neurons together with HEK-293 cells the % of Met-Enkephalin responses ( Figure 2G or 2J) were normalized as ((compound/Met-Enkephalin)-Met-Enkephalin) thus, Met-Enkephalin response is set to 0. For both HEK-293 cells and native neurons positive and negative values denote a better or a lower response as compared to Met-Enkephalin, respectively.
To calculate bias, ligand signaling efficiency was also quantified using the operational model of agonism and the transduction ratios (τ/KA) were determined using the following equations, as previously described Kenakin & Christopoulos, 2013; Nagi & Pineyro, 2016; van der Westhuizen et al, 2014) :
E is the effect of the ligand, [A] is the concentration of the agonist, Em is the maximal response, Basal is the response level in the absence of agonist, LogKA is the logarithm of the functional equilibrium dissociation constant of the agonist, n is the slope of the transducer function that links occupancy to response and LogR is the logarithm of the "transduction coefficient" (or "transduction ratio"), τ/KA. τ is an index of the coupling efficiency of the agonist (efficacy).
For each of the tested compounds, the activity was compared to Met-Enkephalin response for a given signaling pathway using the following equation: Δlog(/KA) = log (/KA)Compound -log (/KA)MetEnk (Eq. 2) For each compound, bias was calculated for Gi2 activation (pathway 1) versus either arrestin2 recruitment or receptor trafficking in the early endosome compartments (pathway2) ( Table S8) using the following equation: ΔΔlog(/KA) = Δlog(/KA)pathway1 -Δlog(/KA)pathway2 (Eq.3)
Statistically significant bias towards either of the pathways was determined after a one-sample t test analysis.
Animals
Male MOR +/+ and MOR -/mice aged 8-16 weeks were bred in-house on a hybrid C57Bl/6J:129SvPas (50:50%) background (Matthes et al, 1996) . Male and female MOR +/+ , MOR Venus/+ , MOR Venus/Venus mice aged 8-16 weeks were bred in-house on a C57Bl/6N background (Neurophenotyping Center, McGill University/Douglas Hospital Research Institute, Montreal, Canada). MOR Venus/Venus mice were generated at the Institut Clinique de la Souris (Illkirch-Graffenstaden, France). MOR Venus/Venus mice (MOR-Venus mice) expressing the mu opioid receptor fused at its C-terminus to a YFP variant, Venus, were generated by homologous recombination. In these mice, the Venus cDNA was introduced into exon 4 of the MOR receptor gene via a targeting construct in which the MOR stop codon has been replaced by a Gly-Ser-Ile-Ala-Thr-linker sequence followed by Venus encoding cDNA. A neomycin resistance gene flanked by FRT sites was transfected into embryonic stem (ES) cells ( Figure S2A) . Two independent homologous recombinants were electroporated with an FLP recombinase expressing plasmid to excise the neomycin gene and microinjected into C57Bl/6N blastocysts. F1 heterozygous progenies were obtained from chimeras crossed with C57Bl/6N (Charles River Laboratories, Wilmington, MA, USA) mice. MOR Venus/+ mice were intercrossed to generate MOR Venus/Venus mice, which are fertile and develop normally. Animals were group-housed and maintained on a 12-hour light/dark cycle (lights on at 8:00 AM) at a controlled temperature (22ºC ± 1ºC). Food and water were available ad libitum throughout all experiments, unless otherwise stated. All experimental procedures were performed in accordance with the guidelines of the Canadian Council of Animal Care, and all animal procedures were approved by the McGill University/Douglas Hospital Animal Care Committee.
RNA Sample Preparation and Isolation. To collect RNA, brain hemispheres were freshly dissected and immediately frozen on dry ice and stored at -80ºC until use. TRIzol(Invitrogen) reagent was added to the samples directly followed by mechanical dissociation to yield a homogenate. Tissue extraction proceeded according to the manufacture's protocol and Dr. Gentle (Takara, Kusatsu, Japan) was added as a precipitate carrier. Total RNA was resuspended in RNase-and DNase-free water (ThermoFisher, Waltham, MA, USA). RNA quantity and quality were evaluated spectrophotometrically by NanoDrop ND2000 (ThermoFisher).
RT-qPCR. RT-qPCR was performed as described previously (Erbs et al, 2015) with some modifications. Briefly, 400 ng of RNA was reverse transcribed using the M-MLV Reverse Transcriptase Kit (Invitrogen) according to the manufacturer's instructions. cDNA was diluted 20 times and then subjected to 45 cycles of amplification by using LightCycler 480 SYBR I Green Master Mix (Roche, Basel, Switzerland) on the LightCycler 480 II Real-Time PCR System (Roche). cDNA samples were loaded in triplicate with 2 µl cDNA and 10 µl final volume. A notemplate control (NTC) reaction, with just water, was included to check for non-specific amplification. The housekeeping gene, B2m, average was subtracted from the average of the triplicate CT values for each sample. Relative fold changes were calculated by the comparative CT method (2^−ΔΔCT) (Livak & Schmittgen, 2001) . were prepared from rapidly dissected brain hemispheres following mouse cervical dislocation, placed on dry ice and stored at -80ºC until use. For each genotype, 4 male or female mice yielded 4 membrane preparations. Results are expressed as the mean of all preparations. Membranes were prepared by homogenizing tissue in 0.25M Sucrose (ThermoFisher) with mechanical dissociation for 30 seconds. Centrifugation followed at 2500 rpm, 4ºC for 10 min. Samples were diluted in TMEN (50mM TrisHCl (pH 7.4), 3mM MgCl2, 0.2mM EGTA, 100mM NaCl) and the samples ultracentrifugated (Optimax-XP, Beckman Coultier, Brea, CA, USA) at 40,000 g, 4ºC for 40 minutes with a MLA-55 rotor (Beckman). The membrane pellet was re-suspended in 0.32M sucrose by 10 strokes with a glass tissue grinder. Protein concentration was determined by the Bradford assay (Bio-Rad, Hercules, CA, USA) with a standard curve of BSA (ThermoFisher) and 3 dilutions of each sample. The membrane preparations were diluted to 0.1 mg/ml and stored at -80ºC in aliquots of 500 µl. For each assay, 5 µg of protein was used per well. Samples were incubated with and without ligands, for 1 hour at 25ºC in assay buffer containing 5 mM GDP and 0.1 nM [ 35 S] GTPγS. After filtration (Cell Harvester, Perkin Elmer), bound radioactivity was quantified by a liquid scintillation counter, TopCount (Perkin Elmer). Non-specific binding was determined by binding in the presence of 10 µM GTPγS and basal activity was determined in the absence of agonist. Calculations and sigmoidal dose-response binding curves were done using GraphPad PRISM 6 (GraphPad Software).
Behavioral Tests in MOR-Venus mice. Morphine induced locomotor activity was examined with mice single housed in an empty novel cage located above an infrared floor. Light intensity of the room was set at about 1.5-foot candles. The trajectories of the mice were analyzed and recorder via an automated tracking system equipped with an infrared-sensitive camera (VideoTrack, ViewPoint Behavior Technology, Lyon, France). Behavioral testing started when the animals were placed in the boxes for a 60-minute habituation period. The mice were injected with 40 mg/kg of morphine or saline and activity was assessed for 2 hours. Morphine-induced
